ArticleBMC gastroenterology2025
The value of fecal calprotectin measured by fluorescent immunochromatography assay in evaluating clinical and endoscopic activity in ulcerative colitis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimFecal calprotectin (FC) levels correlate with clinical or endoscopic activity in ulcerative colitis (UC), however, these values vary widely between detection methods, and optimal cut-off values remain debated. To assess the correlation between FC levels measured by fluorescent immunochromatography assay (FICA) and disease activity and to identify optimal cut-off values for predicting clinical and endoscopic activity in UC.
methodThe study included patients hospitalized at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2021 and June 2022. All the patients had a confirmed diagnosis of UC. Clinical activity was determined using the partial Mayo score (pMS), and endoscopic activity was determined using the ulcerative colitis endoscopy index of severity (UCEIS) and Mayo endoscopic score (MES).
resultsIn 110 patients with UC, FC levels were significantly correlated with pMS (r = 0.609, P < 0.001), UCEIS (r = 0.751, P < 0.001) and MES (r = 0.635, P < 0.001). Moreover, the optimal FC cut-off values to predict clinical activity (pMS 3-12) and endoscopic activity (UCEIS 1-8 or MES 1-3) were 57.38 µg/g and 53.30 µg/g, respectively.
conclusionFC measured by FICA was a good predictor of clinical and endoscopic activity in patients with UC. When using FICA to detect FC, the optimal cut-off value to identify clinical activity in patients with UC was 57.38 µg/g, and a lower value should be chosen to optimize the identification of endoscopic activity in these patients, which was determined as 53.30 µg/g.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.